XML 16 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
In Thousands, except Share data, unless otherwise specified
 12 Months Ended
Apr. 30, 2013
Apr. 30, 2012
Operating revenue:    
Personalized oncology solutions $ 2,390 $ 2,332
Translational oncology solutions 5,933 4,817
Total operating revenue 8,323 7,149
Costs and operating expenses:    
Cost of personalized oncology solutions 2,672 2,356
Cost of translational oncology solutions 2,656 2,543
Research and development 1,920 2,937
Sales and marketing 2,665 2,928
General and administrative 4,631 5,450
Total costs and operating expenses 14,544 16,214
Loss from operations. (6,221) (9,065)
Other (expense) income:    
Change in fair value of warrant liability (74) 417
Other expense (25) (15)
Total other (expense) income (99) 402
Net loss before income tax expense.. (6,320) (8,663)
Provision for (benefit from) income tax . 10 (2)
Net loss $ (6,330) $ (8,661)
Net loss per common share outstanding, including redeemable common stock, basic and diluted (in dollars per share) $ (0.12) $ (0.19)
Weighted average common shares outstanding, including redeemable common stock, basic and diluted (in shares) 52,046,766 46,815,000